WO2012141989A3 - Immunogens - Google Patents
Immunogens Download PDFInfo
- Publication number
- WO2012141989A3 WO2012141989A3 PCT/US2012/032720 US2012032720W WO2012141989A3 WO 2012141989 A3 WO2012141989 A3 WO 2012141989A3 US 2012032720 W US2012032720 W US 2012032720W WO 2012141989 A3 WO2012141989 A3 WO 2012141989A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- immunogens
- hiv
- inducing
- general
- immune response
- Prior art date
Links
- 230000028993 immune response Effects 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1036—Retroviridae, e.g. leukemia viruses
- C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
- C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- AIDS & HIV (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Hematology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
The present invention relates, in general, to HIV and, in particular, to novel immunogens suitable for use in inducing an immune response to HIV.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161473748P | 2011-04-09 | 2011-04-09 | |
US61/473,748 | 2011-04-09 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2012141989A2 WO2012141989A2 (en) | 2012-10-18 |
WO2012141989A3 true WO2012141989A3 (en) | 2013-01-17 |
Family
ID=47009920
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2012/032720 WO2012141989A2 (en) | 2011-04-09 | 2012-04-09 | Immunogens |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2012141989A2 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2912055A4 (en) * | 2012-10-26 | 2016-06-08 | Univ Duke | Synthetic env proteins |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080213296A1 (en) * | 2000-09-22 | 2008-09-04 | Duke University | Immunogen |
-
2012
- 2012-04-09 WO PCT/US2012/032720 patent/WO2012141989A2/en active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080213296A1 (en) * | 2000-09-22 | 2008-09-04 | Duke University | Immunogen |
Non-Patent Citations (3)
Title |
---|
CHITRAPORN KARNASUTA ET AL.: "Antibody-dependent cell-mediated cytotoxic responses in participants enrolled in a phase 1/11 ALVAC-HIV/AIDSVAX B/E prime-boost HIV-1 vaccine trial in Thailand", VACCINE, vol. 23, no. 19, 2005, pages 2522 - 2529 * |
JOHN P. MOORE ET AL.: "Antibody cross-competition analysis of the human immunodeficiency virus type 1 gp120 exterior envelope glycoprotein", JOURNAL OF VIROLOGY, vol. 70, no. 3, 1996, pages 1863 - 1872 * |
SUPACHAI RERKS-NGARM ET AL.: "Vaccination with ALVAC and AIDSVAX to prevent HIV-1 Infection in Thailand", THE NEW ENGLAND JOURNAL OF MEDICINE, vol. 361, no. 23, 2009, pages 2209 - 2220, XP009141609 * |
Also Published As
Publication number | Publication date |
---|---|
WO2012141989A2 (en) | 2012-10-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1208216A1 (en) | Drug-conjugates, conjugation methods, and uses thereof | |
HK1212935A1 (en) | Broadly-neutralizing anti-hiv antibodies hiv | |
IL236348A0 (en) | Anti-jagged antibodies, compositions comprising the same and uses thereof | |
IL233934B (en) | Cd47 antibodies, compositions comprising the same and uses thereof | |
WO2013021279A3 (en) | Highly galactosylated antibodies | |
WO2014071419A3 (en) | Novel fusion molecules and uses thereof | |
EP2917360A4 (en) | Antibodies to s. aureus surface determinants | |
WO2014083438A3 (en) | Nitric oxide increasing nutritional supplements and methods | |
WO2012100224A3 (en) | Preparation of metal-triazolate frameworks | |
WO2013054199A3 (en) | Cmv antigens and uses thereof | |
CA143394S (en) | Microwavable bag | |
CA144229S (en) | Drinking flask | |
WO2012162534A3 (en) | Hyaluronic acid-binding synthetic peptidoglycans, preparation, and methods of use | |
PH12015501101A1 (en) | Method for eliciting an immune response to an immunogen | |
WO2012109238A3 (en) | Methods for increasing immune responses using agents that directly bind to and activate ire-1 | |
CA147873S (en) | Teapot | |
AU346731S (en) | 1. Chair without arms 2. chair with arms | |
WO2014091167A3 (en) | Cyclopropylboronic compounds, method for preparing same and use thereof | |
EP2720866A4 (en) | Partially opaque-partially clear laminates and methods thereof. | |
WO2013052095A3 (en) | Vaccine | |
WO2011101312A3 (en) | Heating arrangement | |
HK1209027A1 (en) | Vesicular formulations, uses and methods | |
WO2014009204A8 (en) | Oxasilacycles and method for the production thereof | |
EP2900693A4 (en) | Adcc-mediating antibodies, combinations and uses thereof | |
EP2902480A4 (en) | Paecilomyces variotii var. brunneolus gpp1101b, and preparation using same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12770536 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 12770536 Country of ref document: EP Kind code of ref document: A2 |